Symbiotec Pharmalab IPO

The Symbiotec Pharmalab mainboard IPO is open between 24 Aug 2026 and 27 Aug 2026, offered at a price band of ₹938–988 per share, and is set to list on NSE and BSE. The IPO seeks to raise ₹1,757 crore. Retail investors bid in lots of 15 shares, a minimum application of ₹14,820.

Issue structure

The offer combines a fresh issue of ₹150 crore with an offer for sale (OFS) of ₹1,607 crore by existing shareholders. Money raised through the fresh issue goes to the company for its stated objects, while OFS proceeds go to the selling shareholders rather than the business.

Objects of the issue

Per the offer document, the company intends to deploy the net proceeds primarily toward prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company (₹112.5 crore), alongside general corporate purposes.

Financials

In FY2026, Symbiotec Pharmalab reported revenue of ₹872.26 crore and a net profit of ₹109.9 crore. Revenue grew from ₹723.33 crore in FY2024 to ₹872.26 crore in FY2026 (+21.0%). Net worth stood at ₹1,158.64 crore at the end of FY2026. At the upper band, that puts the issue at roughly 55.4× FY2026 earnings (P/E), a figure worth comparing against listed peers in the sector.

Valuation

At the upper band, the issue is priced at 56.81× post-issue earnings and 5.35× book value, against a return on net worth of 9.48%. These ratios come from the offer document and are for comparison, not a recommendation.

Peer comparison

The offer document names listed peers including Cohance Lifesciences and Concord Biotech, with a median peer P/E of about 91.4×. The issue's own post-issue P/E works out to 56.81×.

Promoters

The promoters of the company are <p>Anil Satwani, Kashish Satwani, Sushil Satwani, Satwani Holdings LLP</p>. Promoter holding stands at 34.47% before the issue and comes down to 0% after listing.

Grey market premium (GMP)

In the unofficial grey market, Symbiotec Pharmalab shares are quoted at a premium of ₹409 implying an expected listing around ₹1,397, about +41.4% over the upper band. Grey market premium is a sentiment indicator set by private dealers, not the company or the exchange — it moves quickly and is not a reliable predictor of the actual listing price.

What to weigh

When evaluating the Symbiotec Pharmalab IPO, the data points most investors look at are the fresh-issue-versus-OFS split, the revenue and profitability trend and the grey market premium. Grey market premium and subscription figures reflect short-term sentiment rather than long-term fundamentals; the figures on this page are for information only and are not investment advice.

About Symbiotec Pharmalab

Symbiotec Pharmalab (Symbiotec Pharmalab Ltd.) is a pharmaceuticals company. It filed its draft red herring prospectus (DRHP) with SEBI on 19-Dec-2025, and received SEBI observations (approval) on 25-Mar-2026. The proposed IPO (fresh capital cum ofs) is expected to list on BSE and NSE. JM Financial is acting as a lead manager. IPO dates, price band and lot size have not been announced yet — this page updates automatically once they are.